[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vera Therapeutics Inc Cl A (VERA)

Vera Therapeutics Inc Cl A (VERA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,317,873
  • Shares Outstanding, K 71,783
  • Annual Sales, $ 0 K
  • Annual Income, $ -299,610 K
  • EBIT $ -383 M
  • EBITDA $ -388 M
  • 60-Month Beta 0.93
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.79

Options Overview Details

View History
  • Implied Volatility 120.44% (+5.49%)
  • Historical Volatility 57.61%
  • IV Percentile 94%
  • IV Rank 82.71%
  • IV High 136.61% on 03/09/26
  • IV Low 43.10% on 08/21/25
  • Expected Move (DTE 11) 5.70 (17.64%)
  • Put/Call Vol Ratio 0.27
  • Today's Volume 366
  • Volume Avg (30-Day) 293
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 23,988
  • Open Int (30-Day) 23,447
  • Expected Range 26.60 to 37.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.60
  • Number of Estimates 5
  • High Estimate $-1.39
  • Low Estimate $-1.72
  • Prior Year $-1.20
  • Growth Rate Est. (year over year) -33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.59 +5.56%
on 06/03/26
39.89 -19.05%
on 05/14/26
-2.23 (-6.46%)
since 05/05/26
3-Month
30.59 +5.56%
on 06/03/26
47.00 -31.30%
on 04/10/26
-6.56 (-16.89%)
since 03/05/26
52-Week
19.07 +69.36%
on 08/07/25
56.05 -42.39%
on 12/24/25
+1.66 (+5.42%)
since 06/05/25

Most Recent Stories

More News
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on June 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee)...

VERA : 32.29 (-3.27%)
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy

Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN) Revised ORIGIN 3 eGFR...

VERA : 32.29 (-3.27%)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on May 4, 2026, the Compensation Committee of the Board of Directors (Compensation Committee)...

VERA : 32.29 (-3.27%)
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

U.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for the accelerated approval of atacicept in adult patients with IgA Nephropathy (IgAN) with a Prescription...

VERA : 32.29 (-3.27%)
Vera Therapeutics Earnings May Reveal the Market Has Already Priced in FDA Approval

Barchart Research What to Expect from VERA Earnings VERA Generated May 4, 2026 Current Price $35.51 EPS Estimate $$-1.26 Consensus Rating Strong Buy Average Move 3.56% Vera Therapeutics Earnings May Reveal...

VERA : 32.29 (-3.27%)
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference

BRISBANE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with...

VERA : 32.29 (-3.27%)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on April 8, 2026, the Compensation Committee of the Board of Directors (Compensation...

VERA : 32.29 (-3.27%)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 23, 2026, the Compensation Committee of the Board of Directors (Compensation...

VERA : 32.29 (-3.27%)
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with...

VERA : 32.29 (-3.27%)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 3, 2026, the Compensation Committee of the Board of Directors (Compensation...

VERA : 32.29 (-3.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Vera Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 36.43
2nd Resistance Point 35.24
1st Resistance Point 33.77
Last Price 32.29
1st Support Level 31.11
2nd Support Level 29.92
3rd Support Level 28.45

See More

52-Week High 56.05
Fibonacci 61.8% 41.92
Fibonacci 50% 37.56
Fibonacci 38.2% 33.19
Last Price 32.29
52-Week Low 19.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.